What is NDC 69097-661?

69097-661 is the product NDC for Fluticasone propionate and Salmeterol, Fluticasone propionate 250 ug/1; Salmeterol xinafoate 50 ug/1 powder, listed with the FDA by Cipla USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What is the active ingredient?

Fluticasone propionate, Salmeterol xinafoate.

Cipla USA Inc., NDC labeler code 69097. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Fluticasone propionate and Salmeterol?

23 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Fluticasone propionate and Salmeterol NDC 69097-661

NDC codes

FDA NDC Directory

Product NDC (as listed)69097-661Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69097-0661Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69097-661-03	6909706610369097066103	1 INHALER in 1 CARTON (69097-661-03) / 60 POWDER in 1 INHALERMarketed from Jul 27, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fluticasone propionate and Salmeterol
Generic name (nonproprietary): fluticasone propionate and salmeterol
Active ingredients: Fluticasone propionate — 250 ug/1Salmeterol xinafoate — 50 ug/1
Dosage form: Powder
Route: Respiratory (Inhalation)
Labeler: Cipla USA Inc.NDC labeler code 69097
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213087
Marketing start: Jul 27, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic beta2-Agonists (Mechanism)Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 69097-661_6a4f271b-bc4d-4e04-b5d2-d8e8a48d7215SPL ID 6a4f271b-bc4d-4e04-b5d2-d8e8a48d7215SPL set ID 1349a04c-2024-42b9-b81d-a7d995716adeRxCUI 896184, 896209, 896228UNII O2GMZ0LF5W, 6EW8Q962A5
Pharmacologic class: Corticosteroid; beta2-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N469097066103 followed by a unit qualifier and the quantity

Package 69097-0661-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 1, 2026.

Indications (excerpt from the label)

Fluticasone propionate and salmeterol inhalation powder is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for: Twice-daily treatment of asthma in patients aged 4 years and older. ( 1.1 ) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). ( 1.2 ) Important limitation of use: Not indicated for relief of acute bronchospasm. ( 1.1 , 1.2 ) 1.1 Treatment of Asthma Fluticasone propionate and salmeterol inhalation powder is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. Fluticasone propionate and salmeterol inhalatio…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 69097-661

What is NDC 69097-661?: 69097-661 is the product NDC for Fluticasone propionate and Salmeterol, Fluticasone propionate 250 ug/1; Salmeterol xinafoate 50 ug/1 powder, listed with the FDA by Cipla USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Fluticasone propionate and Salmeterol.
What is the active ingredient?: Fluticasone propionate, Salmeterol xinafoate.
Who is the labeler?: Cipla USA Inc., NDC labeler code 69097. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Fluticasone propionate and Salmeterol?: 23 other product NDCs are listed under this name. See all Fluticasone propionate and Salmeterol NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Fluticasone propionate and Salmeterol NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Fluticasone propionate and Salmeterol	Fluticasone propionate 100 ug/1; Salmeterol xinafoate 50 ug/1	PowderRespiratory (Inhalation)	Cipla USA Inc.	69097-662	69097-0662-03
Fluticasone propionate and Salmeterol	Fluticasone propionate 500 ug/1; Salmeterol xinafoate 50 ug/1	PowderRespiratory (Inhalation)	Cipla USA Inc.	69097-663	69097-0663-03
Fluticasone Propionate and Salmeterol	Salmeterol xinafoate 50 ug/1; Fluticasone propionate 100 ug/1	PowderRespiratory (Inhalation)	Lannett Company, Inc.	0527-6010	00527-6010-06
fluticasone propionate and salmeterol	Salmeterol xinafoate 50 ug/1; Fluticasone propionate 100 ug/1	PowderRespiratory (Inhalation)	REMEDYREPACK INC.	70518-4406	70518-4406-00
Fluticasone Propionate and Salmeterol	Salmeterol xinafoate 50 ug/1; Fluticasone propionate 250 ug/1	PowderRespiratory (Inhalation)	Lannett Company, Inc.	0527-6011	00527-6011-06
fluticasone propionate and salmeterol	Salmeterol xinafoate 50 ug/1; Fluticasone propionate 100 ug/1	PowderRespiratory (Inhalation)	Preferred Pharmaceuticals Inc.	68788-8704	68788-8704-06
fluticasone propionate and salmeterol	Salmeterol xinafoate 50 ug/1; Fluticasone propionate 250 ug/1	PowderRespiratory (Inhalation)	REMEDYREPACK INC.	70518-3968	70518-3968-00
fluticasone propionate and salmeterol	Salmeterol xinafoate 50 ug/1; Fluticasone propionate 250 ug/1	PowderRespiratory (Inhalation)	Preferred Pharmaceuticals Inc.	68788-8453	68788-8453-06
fluticasone propionate and salmeterol	Fluticasone propionate 500 ug/1; Salmeterol xinafoate 50 ug/1	PowderRespiratory (Inhalation)	Teva Pharmaceuticals USA, Inc.	0093-7516	00093-7516-31
fluticasone propionate and salmeterol	Fluticasone propionate 100 ug/1; Salmeterol xinafoate 50 ug/1	PowderRespiratory (Inhalation)	Teva Pharmaceuticals USA, Inc.	0093-7517	00093-7517-31

All 24 Fluticasone propionate and Salmeterol NDCs

Other NDCs under ANDA 213087

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213087
Product	Strength	Form · route	Labeler	Product NDC
Fluticasone propionate and Salmeterol	Fluticasone propionate 100 ug/1; Salmeterol xinafoate 50 ug/1	PowderRespiratory (Inhalation)	Cipla USA Inc.	69097-662
Fluticasone propionate and Salmeterol	Fluticasone propionate 500 ug/1; Salmeterol xinafoate 50 ug/1	PowderRespiratory (Inhalation)	Cipla USA Inc.	69097-663